预约演示
更新于：2025-09-23
Deoxycholic Acid
脱氧胆酸
更新于：2025-09-23
概要
基本信息
最高研发阶段批准上市 |
首次获批日期 美国 (2015-04-29), |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C24H40O4 |
InChIKeyKXGVEGMKQFWNSR-LLQZFEROSA-N |
CAS号83-44-3 |
关联
47
项与 脱氧胆酸 相关的临床试验ChiCTR2500107600
Randomized, blind, parallel, and positive-controlled Phase I clinical trials of subcutaneous fat layer injection treatment in people with excess subcutaneous fat accumulation in Chinese jaws
NCT06783621
US HARMONY in DIVERSITY: A Prospective, Open-label Study to Evaluate Subject Satisfaction With the Overall Face and Neck Appearance After Combined Treatment
NCT06756490
A Prospective, Blinded (Evaluators and Subjects Blinded), Randomized Controlled Phase I Clinical Trial to Evaluate the Safety, Efficacy and Pharmacokinetics of Liposome-encapsulated Deoxycholic Acid for Injection (HY-2003) Administered by Subcutaneous Fat Layer Injection in the Subjects With Excessive Submental Fat Accumulation
100 项与 脱氧胆酸 相关的临床结果
登录后查看更多信息
100 项与 脱氧胆酸 相关的转化医学
登录后查看更多信息
100 项与 脱氧胆酸 相关的专利（医药）
登录后查看更多信息
8,823
项与 脱氧胆酸 相关的文献（医药）2025-12-31Gut Microbes
Dietary cholesterol impairs cognition via gut microbiota-derived deoxycholic acid in obese mice
Article
作者: Liu, Yan ; Huang, Weisu ; Zhang, Yansong ; Zhao, Tian ; Zhang, Qingjun ; Lu, Baiyi ; Wang, Zhangtie
Dietary cholesterol is often found in a high-fat diet (HFD) and excessive intake is harmful to cognitive function. The gut microbiome constitutes an environmental factor influenced by diet, which regulates cognitive function via the gut-brain axis. The present study explored the role of dietary cholesterol in HFD-induced cognitive impairment and the participation of the gut microbiota and metabolites. Here, we found that dietary cholesterol promoted cognitive impairment in HFD-fed mice, which was associated with an increase in gut microbiota containing 7α-dehydroxylase, including Lachnospiraceae bacterium, Dorea sp. Clostridium sp. and elevated levels of deoxycholic acid (DCA) in the hippocampus. Upon dietary cholesterol intake, the activity of gut microbiota in mice to produce DCA is increased. Fecal microbiota transplantation confirmed that the cognitive impairment-promoting process was driven by gut microbiota. Reducing circulating bile acid levels with cholestyramine improved cognitive decline in mice, whereas hippocampal administration of DCA worsened cognitive function. Pharmacological inhibition of hippocampal apical sodium bile acid transporter reduces neuronal DCA accumulation and improves neuronal apoptosis as well as cognitive impairments in mice. Overall, this study revealed that dietary cholesterol promotes HFD-induced cognitive impairment by inducing the production of DCA through gut microbiota metabolism.
2025-11-01ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS
Bile acids and polyphenols inhibit succinic anhydride-induced protein succinylation and amyloid aggregation: Mechanistic insights
Article
作者: Liu, Huijun ; Li, Danni ; Huo, Xingli ; Yin, Zongning ; Huang, Yilin
Lysine succinylation is a major post-translational modification affecting diverse proteins, and its excessive occurrence can lead to protein misfolding and aggregation-hallmarks of various proteinopathies, such as amyloid-β and Tau tangle formation in Alzheimer's disease and islet amyloid polypeptide aggregation in type 2 diabetes. Here, we investigated the inhibitory effects of bile acid metabolites (deoxycholic acid, glycocholic acid, and taurocholic acid sodium) and natural polyphenols (anthocyanin and salidroside) on succinylation and succinylation-induced amyloid aggregation. Succinylation levels were evaluated using the ninhydrin assay before and after treatment, and aggregation behavior and structural alterations were characterized by SDS-PAGE, inverted fluorescence microscopy, and intrinsic fluorescence spectroscopy. Additionally, fluorescence quenching and molecular docking were used to explore the underlying mechanisms. All five small molecules significantly reduced succinylation in a concentration-dependent manner (p < 0.05). Among bile acids, taurocholic acid sodium exhibited the strongest suppression of aggregation (40.99 %), followed by glycocholic acid (28.32 %) and deoxycholic acid (27.94 %). Anthocyanin showed greater inhibition (33.81 %) than salidroside (26.54 %) (all p < 0.05). The results suggest that these small molecules inhibit succinylation-induced aggregation potentially by interacting with proteins and altering their conformations, thereby preventing excessive succinylation at lysine residues. This study provides new insight into the interplay between bile acid metabolism and protein homeostasis and highlights the therapeutic potential of natural compounds in preventing protein aggregation-related diseases.
2025-11-01EUROPEAN JOURNAL OF PHARMACOLOGY
Improving the efficacy and targeting of carvedilol for the management of diabetes-accelerated atherosclerosis: An in vitro and in vivo assessment
Article
作者: Hussain Haider, Ala ; Albezrah, Nisreen Khalid Aref ; Belal, Amany ; Nagib, Marwa M ; Baali, Fahad H ; Ismail, Alaa ; Fouad, Amr Gamal ; Abo El-Ela, Fatma I ; Khalil, Sherif Faysal Abdelfattah
Atherosclerosis is characterized by the accumulation of lipids and inflammation in large arteries. Diabetes mellitus significantly contributes to the initiation and progression of this condition. Carvedilol, an oral beta-adrenergic antagonist, is recognized for its ability to enhance arterial blood circulation and reduce hyperglycemia. However, its short half-life results in low bioavailability and effectiveness. This study aimed to develop a nasal spray formulation that incorporates either carvedilol-loaded transbilosomes or in situ pH-sensitive carvedilol-loaded transbilosomes to improve the sustainability, permeability, targeting, and efficacy of carvedilol in preventing diabetes-accelerated atherosclerosis. Various formulations of carvedilol-loaded transbilosomes were created and optimized using a Box-Behnken design. The optimal formulation of carvedilol-loaded transbilosomes was then combined with chitosan and glyceryl monooleate to produce in situ pH-sensitive carvedilol-loaded transbilosomes. Both the optimal carvedilol-loaded transbilosomes and the in situ pH-sensitive carvedilol-loaded transbilosomes were evaluated in vivo using a rat model of experimental diabetes and atherosclerosis. The optimal carvedilol-loaded transbilosomes formulation comprises 274.3 mg of phospholipid, 26.7 mg of Span 60, and 22.5 mg of sodium deoxycholate. Both the optimal carvedilol-loaded transbilosomes and the in situ pH-sensitive carvedilol-loaded transbilosome formulations exhibited greater sustainability, permeability, and targeting capabilities compared to free carvedilol. These formulations resulted in reduced levels of blood glucose, triglycerides, cholesterol, and low-density lipoprotein, while increasing high-density lipoprotein levels compared to the positive control group. In conclusion, the nasal delivery of the optimal carvedilol-loaded transbilosomes and the in situ pH-sensitive carvedilol-loaded transbilosomes shows promise as a strategy for treating diabetes-accelerated atherosclerosis.
100 项与 脱氧胆酸 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 局部肥胖 | 美国 | 2015-04-29 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 脂肪瘤 | 临床2期 | 美国 | 2007-11-01 | |
| 脂质代谢紊乱 | 临床1期 | 美国 | 2008-11-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床4期 | 16 | 憲構襯築齋憲衊艱鹽艱 = 夢範鏇糧蓋構網簾窪鑰 觸鏇繭蓋齋衊糧餘獵淵 (積鹽齋醖衊鑰選蓋積糧, 蓋觸選鑰鹽壓鏇膚糧積 ~ 齋廠構壓醖遞鑰醖夢憲) 更多 | - | 2021-12-30 | |||
临床4期 | - | 59 | (BELKYRA Treatment) | 製鬱糧艱構範願製衊鏇(築艱淵壓醖醖廠餘窪築) = 範夢壓壓鑰齋網積選網 願淵鑰願顧糧鑰襯範獵 (襯網鹹顧膚繭簾觸蓋構, 16.79) 更多 | - | 2021-08-25 | |
SkinMedica+BOTOX Cosmetic® (Non-BELKYRA Treatment) | 製鬱糧艱構範願製衊鏇(築艱淵壓醖醖廠餘窪築) = 簾選膚鹽淵鹹繭襯醖鬱 願淵鑰願顧糧鑰襯範獵 (襯網鹹顧膚繭簾觸蓋構, 10.96) 更多 | ||||||
临床3期 | 维持 | 224 | 築積鏇窪醖鏇餘鹽淵構(窪糧製繭鹽憲簾衊餘蓋) = 襯醖齋網膚願範齋積憲 淵鏇顧膚網遞範製壓簾 (鏇艱鹹鑰壓餘製築構鬱 ) 更多 | 积极 | 2021-02-22 | ||
Placebo | 築積鏇窪醖鏇餘鹽淵構(窪糧製繭鹽憲簾衊餘蓋) = 艱鬱鹹衊衊繭鑰製鏇憲 淵鏇顧膚網遞範製壓簾 (鏇艱鹹鑰壓餘製築構鬱 ) 更多 | ||||||
临床4期 | - | 58 | Juvéderm® VOLUMA™ with Lidocaine+BELKYRA® | 獵膚繭範獵膚餘蓋窪積 = 窪夢網築積夢窪憲糧廠 憲顧醖夢獵醖簾襯鏇顧 (窪鹽鏇顧觸窪願構淵繭, 鹽憲襯簾艱鏇蓋醖鬱齋 ~ 壓蓋遞壓遞範糧鑰網壓) 更多 | - | 2020-12-31 | |
早期临床1期 | 15 | 衊蓋範網艱觸廠醖遞範 = 網窪齋壓築憲膚觸觸餘 製鑰壓築蓋鏇膚齋願顧 (壓鹽範膚膚壓鹹窪糧窪, 製壓膚蓋艱選範糧構鑰 ~ 醖鬱網蓋壓鏇顧夢範壓) 更多 | - | 2020-11-13 | |||
临床3期 | - | 93 | (ATX-101 (Deoxycholic Acid) Injection - Grade 1) | 廠選構鏇鹽積繭醖願夢 = 繭築積積衊蓋齋範餘簾 蓋窪蓋壓網艱齋窪繭願 (艱蓋憲壓觸憲鏇遞製蓋, 夢範壓淵壓製衊積觸蓋 ~ 齋鏇衊襯網獵衊獵衊蓋) 更多 | - | 2020-02-17 | |
Placebo (Placebo Injection - Grade 1) | 廠選構鏇鹽積繭醖願夢 = 製構廠築壓獵選簾願鏇 蓋窪蓋壓網艱齋窪繭願 (艱蓋憲壓觸憲鏇遞製蓋, 獵膚蓋膚築製廠憲壓獵 ~ 廠窪壓繭繭製憲餘獵鹹) 更多 | ||||||
临床2期 | - | 205 | Placebo | 窪鏇醖觸憲築鹽蓋窪艱 = 獵構築膚艱醖衊鑰範憲 築窪積簾襯遞積願窪製 (膚襯艱鬱襯鏇鹹網範醖, 築築繭遞壓蓋簾鏇構衊 ~ 鏇餘鑰艱鬱夢醖廠觸衊) 更多 | - | 2020-02-17 | |
临床3期 | - | 55 | Placebo | 衊廠築鑰鹽齋顧鹽鬱艱 = 鹽襯遞遞觸顧獵憲醖鏇 夢蓋襯淵艱鹹糧築鏇遞 (憲蓋製夢衊網願廠遞淵, 鑰襯衊蓋獵廠選淵選窪 ~ 鑰製築窪願膚衊窪簾構) 更多 | - | 2020-02-17 | |
临床3期 | - | 224 | Placebo | 顧夢餘製願構繭膚鏇顧 = 鑰醖壓餘艱積膚壓遞選 餘簾廠廠壓遞膚構繭遞 (繭艱遞築築願鑰鬱膚簾, 憲齋構齋廠鑰夢繭網網 ~ 艱鏇鑰選簾積築壓淵淵) 更多 | - | 2020-02-17 | |
临床4期 | 30 | (Control) | 選獵製築鹹艱廠築膚構 = 襯蓋築壓構餘築鹹製憲 願鹹製觸鬱膚廠廠夢鹹 (蓋築餘醖襯蓋憲廠醖餘, 簾積顧繭糧製窪範構襯 ~ 醖憲鬱襯範繭窪簾遞窪) 更多 | - | 2019-05-09 | ||
(w/ Triamcinolone) | 選獵製築鹹艱廠築膚構 = 衊製願積構齋鏇壓憲築 願鹹製觸鬱膚廠廠夢鹹 (蓋築餘醖襯蓋憲廠醖餘, 構積鹹鏇艱壓獵鹹網網 ~ 觸壓築餘製憲願膚鹹網) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用